On September 1, 2022 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, reported that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. ("FutureChem") (KOSDAQ: 220100ks), a leading Korean radiopharmaceutical company developing innovative medicines and imaging analysis technology for targeting and treating cancer and neurodegenerative diseases (Press release, PharmAbcine, SEP 1, 2022, View Source;bmode=view&idx=12740723&t=board [SID1234649179]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, both companies will conduct collaborative research utilizing antibody assets discovered from PharmAbcine’s proprietary fully human antibody library called "HuPhage" and FutureChem’s development platform for innovative radiopharmaceuticals.

Radiopharmaceuticals are radioactive agents that are utilized for the diagnosis of infection, vessel-related diseases, bone/bone marrow diseases, tumors, and other diseases in heart, lung, kidney, liver etc. Using larger amount of radiation, some radiopharmaceuticals can be used to treat cancers by destroying the affected tissues.

"In addition to previous research collaboration agreements with other notable biotech companies that specialize in mRNA therapeutics, this partnership will provide other new possibilities to expand our R&D scope from the standard antibody therapeutics to novel diagnostics and treatment options, which are needed direly in the market," said Dr. Jin-San Yoo, CEO of PharmAbcine. "We look forward to collaborating with FutureChem, one of key global leaders of radiopharmaceuticals development, to produce critical achievements in the future."

On September 1, 2022 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi’s 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET (Press release, Ultragenyx Pharmaceutical, SEP 1, 2022, View Source [SID1234618878]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On September 1, 2022 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported it will present posters at four upcoming U.S. and international medical conferences in September (Press release, Scynexis, SEP 1, 2022, View Source [SID1234618895]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United States

Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting – September 7-9, 2022, Albuquerque, N.M.

Title: Outcomes of Oral Ibrexafungerp in Refractory Patients with Candida Infections from an Open-Label Study in Patients with Serious Fungal Infections (FURI)
Date: Friday, September 9
Time: 3:30 pm – 5:00 pm MDT
Presenter: Nkechi Azie, M.D.

Title: Outcomes of Oral Ibrexafungerp in the Treatment of 10 Patients with Candida auris Infections, from the CARES Study
Date: Friday, September 9
Time: 3:30 pm – 5:00 pm MDT
Presenter: Nkechi Azie, M.D.
World Anti-Microbial Resistance (AMR) Congress – September 7-9, 2022, National Harbor, Md.

Title: Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of CDC Urgent Threat Pathogen, Candida auris
Date: Wednesday, September 7, and Thursday, September 8
Time: 10:20 am EDT both days
Presenter: Thomas King, MS, MPH
International

International Immunocompromised Host Society (ICHS) – September 8-11, 2022, Basel, Switzerland

Title: Oral Ibrexafungerp Outcomes in Patients with Chronic Mucocutaneous Candidiasis (CMC)
Date: Saturday, September 10
Time: 10:00 am -10:30 am CEST
Presenters: Riina Rautemma-Richardson and Chris Eades, Manchester University
21st Congress of the International Society for Human and Animal Mycology (ISHAM) –September 20-24, 2022, New Delhi, India

Title: All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)
Date: Wednesday, September 21
Time: 12:30 pm – 1:30 pm IST
Presenter: Juergen Prattes, M.D., Medical University of Graz

Title: Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
Date: Wednesday, September 21
Time: 12:30 pm – 1:30 pm IST
Presenter: Juergen Prattes, M.D., Medical University of Graz

On September 1, 2022 Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, reported that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the dosing of the third cohort (Press release, Avacta, SEP 1, 2022, View Source [SID1234618912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Avacta’s Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the third cohort dosed with AVA6000 at 160mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 200mg/m2.

AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION FAP-activated delivery platform to improve its safety and therapeutic index. AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein α (FAP) which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression. Anthracyclines such as doxorubicin, a generic chemotherapeutic agent, with a market size that is expected to grow to $1.38bn by 20241, are widely used as part of standard of care in several tumour types, but its use is limited by cumulative dose toxicity associated with cardiomyopathy.

Dr Alastair Smith, Chief Executive Officer of Avacta, commented: "We are very much encouraged by this recommendation from the SDMC to move onto the fourth dose cohort in our ongoing ALS-6000-101 Phase 1 dose escalation study. This very positive progress reflects the safety profile and tolerability demonstrated in patients enrolled in the study to date."

On September 1, 2022 BCI Pharma reported that it will attend the XXVII EFMC International Symposium on Medicinal Chemistry in Nice from September 4-8, 2022 and present its promising research program targeting tumor-associated macrophages (Press release, BCI Pharma, SEP 1, 2022, View Source [SID1234618860]). Mode of action and efficacy data of our preclinical candidate will be discussed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!